ERBB2 and breast carcinoma: In addition, we found that the combined therapeutic approach of affibody-directed CAR-NK with doxorubicin-loaded nanodrug achieved synergistic treatment effects against HER2-positive breast cancer, indicating an increased anti-tumor effect of targeted chemotherapy for affibody-directed CAR-NK immunotherapy.